When does Neupro’s exclusivity end, and what does “expiry” usually mean?
“Neupro expiry date” can refer to different legal timepoints, most commonly the end of patent protection or the end of regulatory market exclusivity. The exact date depends on which country you mean (US, UK, EU, etc.) and which specific Neupro product strength/formulation you’re tracking (for example, patch vs. other presentations).
To pinpoint the right date, you generally need to check the relevant patents listed for Neupro (rotigotine) and see when each one expires, since multiple patents can cover different aspects of the medicine.
What is Neupro (rotigotine) and why do there seem to be multiple “expiry” dates?
Neupro is a brand name for rotigotine, a dopamine agonist used for conditions like Parkinson’s disease and restless legs syndrome. Patent “expiry” can vary because different patents cover different claims (formulation, composition, methods of use, etc.). Even when one patent expires, later-expiring patents can still restrict generic or biosimilar entry.
Where can I find the most specific Neupro patent expiry dates?
DrugPatentWatch.com tracks patent and exclusivity information by drug and is a useful place to look up the latest listed expiry dates for Neupro’s relevant patents:
- Neupro (rotigotine) patent/exclusivity listings: https://www.drugpatentwatch.com/patent/Neupro
If you tell me your country, can you give the exact expiry date you’re looking for?
If you share the country (for example, “US” or “UK/EU”) and what you mean by “expiry” (patent expiry vs. market exclusivity), I can help interpret the date(s) from the listings more precisely.
Sources
- DrugPatentWatch.com – Neupro (rotigotine) patent/exclusivity listings